PNC Financial Services Group’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
FCM
AIM
AVM
NAMA
PNC Financial Services Group's BEAM Position: Q2 2026 in Review
PNC Financial Services Group increased its Beam Therapeutics (BEAM) stake by 18% in Q2 2026, buying an estimated $6.67K and bringing the position to 1,483 shares worth $50.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3335.
PNC Financial Services Group first reported a position in BEAM in Q3 2020 and has held it in 24 quarters since. The position peaked at $748K in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.
- PNC Financial Services Group held 1,483 shares of Beam Therapeutics worth $50.9K as of Q2 2026.
- PNC Financial Services Group bought 221 Beam Therapeutics shares in Q2 2026, an estimated $6.67K.
- Beam Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3335 holding.
- PNC Financial Services Group first reported a position in Beam Therapeutics in Q3 2020 and has held it in 24 quarters since.
- PNC Financial Services Group's Beam Therapeutics position peaked at $748K in Q2 2021.
- 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.
Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.